TLSINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as TLSIW
TriSalus Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.53−0.10 (-2.75%)
Close on Oct 19, 2026
- Market cap
- $205.79M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
23M
Shares held, 13F filers
Institutional holders
79
12 new, 15 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
12 buys · 15 sales
Net bought $3.47M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Frankenius Equity AB | 6,989,748 | 14.00% | 13D (active) amendment | Jul 31, 2025 |
| Paul Frankenius | 6,732,516 | 20.50% | 13D (active) amendment | Apr 30, 2025 |
| Mathew P. Arens | 6,596,242 | 10.74% | 13G (passive) amendment | Jun 30, 2026 |
| Utmost Group PLC | 3,503,385 | 5.71% | 13G (passive) | Mar 31, 2026 |
| James J. Pallotta | 3,188,711 | 5.20% | 13G (passive) amendment | May 15, 2026 |
| Mats Wahlstrom | 2,987,881 | 6.00% | 13D (active) amendment | Jul 31, 2025 |
| Nantahala Capital Management, LLC | 2,000,000 | 5.29% | 13G (passive) | Jun 30, 2025 |
| Lombard International Assurance S.A. | 1,975,588 | 6.74% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TLSI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| First Light Asset Management, LLC | 6,552,491 | – | $29.81M | +1,485,664 | 1.81% |
| BlackRock, Inc. | 2,659,218 | – | $12.10M | +1,159,671 | 0.00% |
| Nantahala Capital Management, LLC | 2,000,000 | – | $9.10M | −70,827 | 0.15% |
| Vanguard Capital Management LLC | 1,729,385 | – | $7.87M | +382,349 | 0.00% |
| Cerity Partners LLC | 1,603,538 | – | $7.30M | +816,266 | 0.01% |
| Geode Capital Management, LLC | 1,190,067 | – | $5.42M | +412,973 | 0.00% |
| Gilder Gagnon Howe & Co LLC | 850,081 | – | $3.87M | −38,434 | 0.04% |
| State Street Corp | 610,963 | – | $2.78M | +282,943 | 0.00% |
| White Pine Capital LLC | 547,577 | – | $2.49M | +183,922 | 0.59% |
| Thompson Siegel & Walmsley LLC | 536,534 | – | $2.44K | −47,040 | 0.04% |
| Kennedy Capital Management LLC | 476,261 | – | $2.17M | −8,981 | 0.04% |
| Morgan Stanley | 401,814 | – | $1.83M | +7,905 | 0.00% |
| Northern Trust Corp | 379,572 | – | $1.73M | +158,099 | 0.00% |
| Vanguard Portfolio Management LLC | 329,464 | – | $1.50M | +164,606 | 0.00% |
| Vanguard Fiduciary Trust Co | 320,956 | – | $1.46M | +102,604 | 0.00% |
| Lionhunter Capital Management, LLC | 300,275 | – | $1.37M | New | 0.62% |
| Perkins Capital Management Inc | 235,101 | – | $1.07M | +5,000 | 0.80% |
| UBS Group AG | 223,047 | – | $1.01M | +143,495 | 0.00% |
| Bank Of America Corp /De/ | 205,342 | – | $934.31K | +3,623 | 0.00% |
| Royce & Associates LP | 200,060 | – | $910.27K | – | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 79 | 23M | 12 / 45 | 10 / 15 | 6M | 4M |
| Q1 2026 | 84 | 21M | 32 / 23 | 14 / 10 | 13M | 1M |
| Q4 2025 | 64 | 11M | 14 / 24 | 14 / 6 | 2M | 0M |
| Q3 2025 | 56 | 10M | 12 / 19 | 10 / 2 | 1M | 0M |
| Q2 2025 | 46 | 8M | 20 / 17 | 2 / 8 | 6M | 0M |
| Q1 2025 | 34 | 3M | 12 / 11 | 1 / 6 | 1M | 0M |
| Q4 2024 | 28 | 2M | 3 / 6 | 9 / 6 | 0M | 0M |
| Q3 2024 | 31 | 2M | 11 / 3 | 9 / 6 | 1M | 0M |
| Q2 2024 | 27 | 2M | 6 / 6 | 9 / 4 | 1M | 0M |
| Q1 2024 | 25 | 1M | 9 / 6 | 5 / 3 | 0M | 0M |
| Q4 2023 | 19 | 1M | 11 / 3 | 1 / 1 | 1M | 0M |
| Q3 2023 | 9 | 0M | 9 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TLSI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,141,870 | – | $5.20M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,116,957 | – | $5.08M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 545,765 | – | $2.48M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 521,754 | – | $2.37M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 450,180 | – | $2.05M | 0.01% | Jun 30, 2026 |
| Royce Smaller-Companies Growth Fund | 200,000 | – | $910.00K | 0.38% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 189,776 | – | $647.14K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 160,188 | – | $728.86K | 0.05% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 143,142 | – | $488.11K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 116,669 | – | $529.68K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 89,608 | – | $407.72K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 68,501 | – | $233.59K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 65,000 | – | $295.75K | 0.20% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 63,898 | – | $290.10K | 0.01% | Jul 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 56,111 | – | $255.31K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Mary T. Szela | CEO and President, Director | 1,077,683 | Jul 1, 2026 |
| David Patience | Chief Financial Officer | 261,107 | Jul 6, 2026 |
| Richard Marshak | Chief Commercial Officer | 128,319 | Jul 1, 2026 |
| Richard Henry Marshall | Chief Medical Officer | 30,000 | Jun 29, 2026 |
| Bryan F. Cox | Chief of Research | 163,415 | Mar 20, 2026 |
| Jodi Devlin | Chief of Clinical Operations | 97,364 | Mar 20, 2026 |
| Jennifer Stevens | Chief Regulatory Officer | 124,110 | Mar 20, 2026 |
| James Emmett Young | Chief Financial Officer | 79,663 | May 21, 2025 |
| Michael P. Stansky | Director | 1,640,420 | May 18, 2026 |
| Mats Wahlstrom | Director | 2,962,030 | May 18, 2026 |
| Gary B. Gordon | Director | 72,510 | May 18, 2026 |
| William Valle | Director | 83,241 | May 15, 2026 |
| Kerry R. Hicks | Director | 2,317,400 | May 15, 2026 |
| David J. Matlin | Director | 7,550,145 | May 15, 2026 |
| Sean Murphy | Director | 679,256 | Jun 27, 2025 |
| Arjun JJ Desai | Director | 247,127 | Jun 27, 2025 |
| Liselotte Hyveled | Director | 10,040 | Jan 6, 2025 |
| Equity AB Frankenius | 10% owner | 6,989,748 | Apr 20, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David Patience Chief Financial Officer | Jul 1, 2026 | Tax withholding | −14,650 | $4.46 | $65.34K | 261,107 |
| Richard Marshak Chief Commercial Officer | Jun 30, 2026 | Award | +561 | $3.87 | $2.17K | 128,319 |
| Mary T. Szela CEO and President, Director | Jun 30, 2026 | Award | +3,990 | $3.87 | $15.44K | 1,077,683 |
| Richard Henry Marshall Chief Medical Officer | Jun 29, 2026 | Award | +60,000 | – | – | 90,000 |
| Richard Marshak Chief Commercial Officer | May 15, 2026 | Sale | −543 | $2.67 | $1.45K | 125,101 |
| Gary B. Gordon Director | May 15, 2026 | Buy | +10,000 | $2.46 | $24.60K | 72,510 |
| Michael P. Stansky Director | May 15, 2026 | Buy | +200,000 | $2.50 | $500.00K | 399,698 |
| Michael P. Stansky Director | May 15, 2026 | Buy | +410,000 | $2.50 | $1.03M | 1,240,722 |
| Mary T. Szela CEO and President, Director | May 15, 2026 | Buy | +39,682 | $2.59 | $102.78K | 1,065,215 |
| Mats Wahlstrom Director | May 15, 2026 | Buy | +60,000 | $2.53 | $151.80K | 147,555 |
| David Patience Chief Financial Officer | May 15, 2026 | Buy | +7,100 | $2.43 | $17.25K | 275,757 |
| Mats Wahlstrom Director | May 14, 2026 | Award | +34,226 | – | – | 87,555 |
| Mats Wahlstrom Director | May 14, 2026 | Award | +37,602 | – | – | 53,329 |
| William Valle Director | May 14, 2026 | Award | +24,553 | – | – | 83,241 |
| William Valle Director | May 14, 2026 | Award | +28,201 | – | – | 58,688 |
| Gary B. Gordon Director | May 14, 2026 | Award | +28,201 | – | – | 37,957 |
| Gary B. Gordon Director | May 14, 2026 | Award | +24,553 | – | – | 62,510 |
| David J. Matlin Director | May 14, 2026 | Award | +28,201 | – | – | 1,300,145 |
| David J. Matlin Director | May 14, 2026 | Award | +23,065 | – | – | 1,323,210 |
| Michael P. Stansky Director | May 14, 2026 | Award | +23,501 | – | – | 810,633 |
| Michael P. Stansky Director | May 14, 2026 | Award | +20,089 | – | – | 830,722 |
| Kerry R. Hicks Director | May 14, 2026 | Award | +28,201 | – | – | 542,790 |
| Mary T. Szela CEO and President, Director | Mar 17, 2026 | Sale | −15,944 | $3.85 | $61.38K | 752,987 |
| Richard Marshak Chief Commercial Officer | Mar 16, 2026 | Sale | −419 | $4.12 | $1.73K | 110,397 |
| Jodi Devlin Chief of Clinical Operations | Mar 16, 2026 | Sale | −273 | $4.12 | $1.12K | 97,364 |
| Jennifer Stevens Chief Regulatory Officer | Mar 16, 2026 | Sale | −774 | $4.12 | $3.19K | 124,110 |
| Bryan F. Cox Chief of Research | Mar 16, 2026 | Sale | −579 | $4.12 | $2.39K | 163,415 |
| Richard Marshak Chief Commercial Officer | Mar 12, 2026 | Sale | −1,589 | $4.09 | $6.50K | 110,816 |
| Jodi Devlin Chief of Clinical Operations | Mar 12, 2026 | Sale | −1,772 | $4.09 | $7.25K | 97,637 |
| Jennifer Stevens Chief Regulatory Officer | Mar 12, 2026 | Sale | −1,552 | $4.09 | $6.35K | 124,884 |
| Bryan F. Cox Chief of Research | Mar 12, 2026 | Sale | −1,467 | $4.09 | $6.00K | 163,994 |
| Mary T. Szela CEO and President, Director | Mar 11, 2026 | Sale | −4,358 | $4.13 | $18.00K | 768,931 |
| Richard Marshak Chief Commercial Officer | Mar 11, 2026 | Sale | −1,449 | $4.13 | $5.98K | 112,405 |
| Jodi Devlin Chief of Clinical Operations | Mar 11, 2026 | Sale | −1,162 | $4.13 | $4.80K | 99,409 |
| Jennifer Stevens Chief Regulatory Officer | Mar 11, 2026 | Sale | −1,204 | $4.13 | $4.97K | 126,436 |
| Bryan F. Cox Chief of Research | Mar 11, 2026 | Sale | −1,138 | $4.13 | $4.70K | 165,461 |
| David Patience Chief Financial Officer | Feb 23, 2026 | Buy | +3,657 | $4.10 | $14.99K | 268,657 |
| Michael P. Stansky Director | Feb 23, 2026 | Buy | +117,198 | $4.10 | $480.51K | 199,698 |
| Michael P. Stansky Director | Feb 23, 2026 | Buy | +243,900 | $4.10 | $999.99K | 787,132 |
| William Valle Director | Feb 23, 2026 | Buy | +30,487 | $4.10 | $125.00K | 30,487 |
| Mary T. Szela CEO and President, Director | Feb 23, 2026 | Buy | +30,487 | $4.10 | $125.00K | 773,289 |
| Gary B. Gordon Director | Feb 23, 2026 | Buy | +9,756 | $4.10 | $40.00K | 9,756 |
| Mary T. Szela CEO and President, Director | Dec 31, 2025 | Award | +2,100 | $4.38 | $9.20K | 1,023,826 |
| Richard Marshak Chief Commercial Officer | Dec 31, 2025 | Award | +449 | $4.38 | $1.97K | 131,758 |
| Bryan F. Cox Chief of Research | Nov 24, 2025 | Award | +40,000 | – | – | 166,599 |
| Jodi Devlin Chief of Clinical Operations | Nov 24, 2025 | Award | +50,000 | – | – | 100,571 |
| David Patience Chief Financial Officer | Nov 24, 2025 | Award | +65,000 | – | – | 265,000 |
| Mary T. Szela CEO and President, Director | Nov 24, 2025 | Award | +125,000 | – | – | 442,802 |
| Mary T. Szela CEO and President, Director | Nov 24, 2025 | Award | +300,000 | – | – | 742,802 |
| Jennifer Stevens Chief Regulatory Officer | Nov 24, 2025 | Award | +50,000 | – | – | 127,640 |
| Richard Marshak Chief Commercial Officer | Nov 24, 2025 | Award | +60,000 | – | – | 113,854 |
| David Patience Chief Financial Officer | Aug 14, 2025 | Award | +200,000 | – | – | 200,000 |
| Equity AB Frankenius 10% owner | Jul 31, 2025 | Conversion | +759,000 | – | – | 6,989,748 |
| David J. Matlin Director | Jul 31, 2025 | Conversion | +330,000 | – | – | 1,271,944 |
| Mary T. Szela CEO and President, Director | Jun 30, 2025 | Award | +2,848 | $4.23 | $12.05K | 596,726 |
| Richard Marshak Chief Commercial Officer | Jun 30, 2025 | Award | +930 | $4.23 | $3.93K | 71,309 |
| Sean Murphy Director | May 19, 2025 | Award | +44,884 | $5.18 | $232.50K | 123,989 |
| Jodi Devlin Chief of Clinical Operations | May 19, 2025 | Sale | −4,764 | $5.18 | $24.68K | 52,764 |
| Jodi Devlin Chief of Clinical Operations | May 19, 2025 | Award | +24,131 | $5.18 | $125.00K | 57,528 |
| Jennifer Stevens Chief Regulatory Officer | May 19, 2025 | Sale | −8,704 | $5.18 | $45.09K | 77,640 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Desai Arjun Board of Directors | Dec 10, 2024 | 30,000 | $135.00K | Dec 10, 2024 | grant-spac |